Actelion Launches New PAH Drug In Vietnam; PharmaLink Gets Commercializing Rights
This article was originally published in PharmAsia News
Executive Summary
SHANGAI - Swiss biopharmaceutical company Actelion inked a deal with Singapore-based PharmaLink to introduce pulmonary arterial hypertension treatment Tracleer (bosentan) to Vietnam, the two companies announced July 10 in Ho Chi Minh City